Intelligent Bio Solutions Completes Key FDA Study for U.S. Drug Screening System — Intelligent Bio Solutions Inc.

Event summary

Intelligent Bio Solutions completed a multi-site Method Comparison Study for its Intelligent Fingerprinting Drug Screening System, enrolling 135 participants across three U.S. clinical sites.
The study evaluated the system's accuracy, specificity, and usability in workplace drug screening environments, critical for FDA 510(k) submission.
All clinical data collection for the FDA 510(k) program is now complete, with data analysis underway and submission targeted for H2 2026.
The study was conducted under ICH GCP guidelines, involving nine operator participants representing typical workplace drug screening personnel.

The big picture

Intelligent Bio Solutions is advancing toward U.S. market entry with a non-invasive, rapid drug screening system that could disrupt workplace safety protocols. The completion of this study marks a critical step in securing FDA clearance for a technology already used internationally in industries like construction and logistics. Success here would position INBS to compete in the multi-billion-dollar U.S. drug testing market.

What we're watching

Regulatory Timing: Whether the FDA 510(k) submission will meet its H2 2026 target and secure clearance for U.S. market entry.
Market Adoption: The pace at which employers in safety-critical industries will adopt non-invasive drug screening technology.
Competitive Positioning: How Intelligent Bio Solutions differentiates its fingerprint sweat analysis from traditional drug testing methods.